等待开盘 11-19 09:30:00 美东时间
-0.090
-1.25%
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
今天 19:40
11月18日,Immix Biopharma(IMMX)收跌3.74%,报7.2美元,成交额720.04万美元,市值6.03亿美元。 行情数据 • 开盘价:7...
11-18 06:58
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a 20.83 percent increase over losses of $(0.24) per share from the same period last year.
11-13 05:47
Immix Biopharma reported positive NEXICART-2 clinical data with an 89% complete response rate and MRD-negativity suggesting up to 98% in the future. The company is advancing commercial readiness, including site activation and team expansions. NEXICART-2 interim results will be presented at ASH 2026. Financials show $340.9M in cash, supporting operations into mid-2028, with plans for BLA submission in mid-2027 and NEXICART-3 initiation in early 20...
11-12 21:15
11月11日,Immix Biopharma(IMMX)收跌2.57%,报8.35美元,成交额686.74万美元,市值6.94亿美元。 行情数据 • 开盘价:...
11-11 06:54
Immix Biopharma will present NXC-201 data at the 68th ASH Annual Meeting in New Orleans on December 14, 2026. The presentation will focus on safety and efficacy results from the Nexicart-2 trial, involving 45 patients with relapsed/refractory AL amyloidosis. AL amyloidosis is a life-threatening disease causing organ failure due to toxic light chain buildup. NXC-201, a BCMA-targeted CAR-T therapy, has received Breakthrough Therapy and Orphan Drug ...
11-04 14:15
11月3日,Immix Biopharma(IMMX)收跌5.47%,报7.26美元,成交额1106.82万美元,市值6.03亿美元。 行情数据 • 开盘价:...
11-03 06:59
10月27日,Immix Biopharma(IMMX)收跌1.1%,报8.06美元,成交额904.33万美元,市值6.7亿美元。 行情数据 • 开盘价:8....
10-27 05:57
10月20-22日上海黄浦江畔,2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势,更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:59